The podocyte in diabetic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Molecular Biology

Background:

• Diabetic kidney disease (DKD) is a major cause of end-stage renal disease (ESRD), approaching epidemic proportions.
• Microalbuminuria, an early marker of DKD, signifies damage to glomerular podocytes, leading to podocytopathies.
• Podocytopathies involve cellular hypertrophy, foot process effacement, detachment, and apoptosis.

Purpose of the Study:

• To review recently identified factors contributing to podocytopathies in DKD.
• To explore the roles of the renin-angiotensin system (RAS), reactive oxygen species (ROS), and other signaling molecules.
• To identify potential novel therapeutic targets for DKD treatment and prevention.

Main Methods:

• Literature review of recently identified factors in DKD-related podocytopathies.
• Analysis of the roles of specific molecular pathways including RAS, ROS, PPARs, AGEs/RAGE, adiponectin, and microRNAs.
• Synthesis of current understanding of signaling events contributing to podocyte injury.

Main Results:

• Several factors, including RAS components (ACE 1/2, prorenin/receptor), ROS, prostanoids, PPARs, AGEs/RAGE, adiponectin, and microRNAs, are implicated in DKD podocytopathies.
• These factors contribute to the cellular damage observed in podocytes.
• Current therapies slow DKD progression but do not halt it.

Conclusions:

• A comprehensive understanding of signaling pathways in DKD podocytopathies is crucial.
• Identifying novel therapeutic targets is essential for developing effective treatments and prevention strategies for DKD.
• Further research into these factors may lead to breakthroughs in managing this prevalent condition.